MAP Pharmaceuticals Inc. Resources | BNET
On last.fm: Create Artist- Based Radio Station

BNET Industries

MAP Pharmaceuticals Inc. (MAPP) is in the Pharma Industry

Profit
Dec 31 2007
($40.0M)
Market Cap
Jul 22 2008
$184.6M

Latest News and Analysis

  • MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference

    MOUNTAIN VIEW, Calif., May 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the Company will present at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008, at 9:00 am ET in New York City. A live webcast of the presentation will...

    Articles 2008-05-16

  • MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results

    MOUNTAIN VIEW, Calif., May 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2008. The net loss for the first quarter ended March 31, 2008 was $14.3 million compared with $6.7 million during the same period in 2007....

    Articles 2008-05-12

  • MAP Pharmaceuticals Secures $20 Million in Debt Financing

    MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the company has secured a $20 million working capital loan. Oxford Finance Corporation, the principal lender, and Silicon Valley Bank, a member company of SVB Financial Group , provided the financing. Proceeds from this...

    Articles 2008-05-07

  • MAP Pharmaceuticals to Present at Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., April 25 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the company will present at the following upcoming investor conferences on April 30th and May 6th, 2008: Morgan Stanley Global Healthcare Conference, Key Biscayne, FL Wednesday, April 30, 2008 9:10 am,...

    Articles 2008-04-25

  • Progressive Following on MAP Pharmaceuticals Inc.

    M2 PRESSWIRE-31 January 2008-Street Tips: Progressive Following on MAP Pharmaceuticals IncC1994-2008 M2 COMMUNICATIONS LTD RDATE:31012008 Stocks were up for a third straight day Friday, following Microsoft's bright forecast and profit earnings that proved to be better than expected. Investors...

    Articles 2008-01-31

  • Has added MAP Pharmaceuticals, Inc. to their watch list.

    M2 PRESSWIRE-30 January 2008-The Maybach Review: Has added MAP Pharmaceuticals, Inc. to their watch list.C1994-2008 M2 COMMUNICATIONS LTD RDATE:30012008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers,...

    Articles 2008-01-30

  • MAP Pharmaceuticals Appoints General Counsel

    Wireless News07-30-2007MAP Pharmaceuticals Appoints General CounselWIRELESS NEWS-July 30, 2007-MAP Pharmaceuticals Appoints General Counsel C2007 10Meters - http://www.10meters.com MAP Pharmaceuticals announced the appointment of Charlene A. Friedman as Vice President, General Counsel and Secretary. Friedman has been practicing law for more than 25 years, including serving as General Counsel at...

    Articles 2007-07-30

  • Plan B, Alli blaze new trails for OTC switch

    Two of the Food and Drug Administration's most recent switch applications--one approved and one under consideration--may provide a road map for pharmaceutical companies looking to bring more complicated regimens to the nonprescription aisles. Duramed's emergency contraceptive Plan B, approved for over the counter sale in August, is the...

    Articles 2007-01-15

  • MAP Pharmaceuticals Selects ClearTrial to Expedite Clinical Trial Planning and Outsourcing

    ClearTrial, LLC, a leading provider ofClinical Trial Operations CTO software, today announced that MAPPharmaceuticals has selected the ClearTrial PlannerTM software to plan,forecast and budget their clinical trials and to help optimize theiroperational execution of those trials. "ClearTrial's software artfully abstracts the complex process of planningclinical studies into an elegant, fast...

    Articles 2005-08-02

  • MAP PHARMACEUTICALS APPOINTS NELSON PRESIDENT/CEO.

    MAP Pharmaceuticals, Inc., Mountain View, Calif., a developer of novel inhaled drug products, has announced the appointment of Timothy S. Nelson as the company's new president and chief executive officer. Nelson also joins the company's board of directors. Thomas Armer, Ph.D., who has served as the...

    Articles 2005-06-01

  • Genomics map pharmaceutical financing

    Biotechnology, and especially genomics, are leading US and Euroean health care financings. Biotechnology deals, and especially genomic deals, are driving the vast majority of financings in the health care market, and the promise of the highly-targeted pharmaceuticals these technologies are producing suggest the wave is far from over. ...

    Articles 2001-01-01

  • The World's Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy. (book reviews)

    The publication of this book, in which the authors present a 'global map' of the pharmaceutical industry, is timely, given that the large multinational corporations composing a major part of the international pharmaceutical' industry are, it seems, at the start of a period of extensive restructuring...

    Articles 1993-10-01

  • page 1 of 1
  • Incorporated: 2003
  • CEO: Mr. Timothy S. Nelson
  • Employees: 72

MAP Pharmaceuticals is a development stage company who uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk. Co. is developing novel inhalation therapies for a broad spectrum of diseases, both respiratory and systemic. Co.'s two most advanced product candidates are: Unit Dose Budesonide and MAP0004. Unit Dose Budesonide is intended to treat pediatric asthma in children from 12 months to eight years of age. MAP0004 is Co.'s proprietary inhaled version of dihydroergotamine, or DHE, intended to treat migraine.

Key Competitors

advertisement
MAP Pharmaceuticals Inc. Company Info

Board of Directors

Mr. Steven A. Elms

Chairman

Mr. Matthew V. McPherron

Mr. Bernard J. Kelley

Mr. Timothy S. Nelson

Dr. Carl S. Goldfischer M.D.

Dr. John G. Freund M.D.

Dr. Thomas A. Armer Ph.D.

Mr. H. Ward Wolff

Ms. Gerri A. Henwood

Contact Information

2400 Bayshore Parkway

Suite 200

Mountain View, CA

http://www.mappharma.com

650 386-3100

NAICS Code

Pharmaceutical Preparation Manufacturing: 325412
Brought to you by IBMSponsored Resources
advertisement